Author(s): Rosenstock J
Given the enormous public health and economic burden posed by the global epidemic of type 2 diabetes mellitus (T2DM), intervention in the prediabetes stage of disease to prevent progression to T2DM and its vascular complications seems the most sensible approach. Precisely how best to intervene remains the subject of much debate. Prudent lifestyle changes have been shown to significantly reduce the risk of progression in individuals with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). Although lifestyle modifications are notoriously difficult to maintain, there is evidence that intensive intervention results in continued preventive benefit after the stopping of structured counselling. A number of drug therapies, including metformin, acarbose, orlistat and rosiglitazone, have also been proven effective in preventing progression from IFG/IGT, but unresolved issues still remain. Specifically, whether large numbers of individuals with glucose dysregulation who may never progress to T2DM should be exposed to the risk of pharmacological adverse effects is a topic of discussion and debate. Furthermore, there are limited data on the effectiveness of implementing interventions during the prediabetic state to prevent cardiovascular complications that may be hyperglycaemia related. A recent American Diabetes Association (ADA) consensus statement on IFG/IGT recommends lifestyle modification for individuals with IFG or IGT. Of note, the ADA consensus statement introduces the option of adding metformin treatment to lifestyle changes in those individuals who have combined IFG/IGT plus an additional risk factor for progression and who also have some features that increase the likelihood of benefiting from metformin treatment. The dipeptidyl peptidase-4 inhibitors are a new class of oral antidiabetic agents that, in addition to being effective in improving glycaemic control, may exert beneficial effects in preserving beta-cell function. These characteristics, combined with a low risk of hypoglycaemia, weight neutrality and what appears - so far - to be a relatively benign tolerability profile, make these agents intriguing candidates for preventive treatment.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/17877541
Author(s): Davis TME
Author(s): National Collaborating Centre for Chronic Conditions
Author(s): Hanif MW, Valsamakis G, Dixon A, Boutsiadis A, Jones AF, et al.
Author(s): Ojo O
Author(s): Masso-Gonzalez EL, Johansson S, Wallander MA, Garcia-Rodriguez LA
Author(s): Sedgwick JEC, Pearce AJ, Gulliford MC
Author(s): Ojo O
Author(s): Alberti KG, Zimmet PZ
Author(s): Nielsen J, Christensen DL
Author(s): Gagnon AJ, McDermott S, Rigol-Chachamovich J, Bandyopadhyay M, Stray-Pedersen B, et al.
Author(s): United Nations, General Assembly
Author(s): Leung G, Stanner S
Author(s): McKeigue PM, Shah B, Marmot MG
Author(s): NICE
Author(s): Chege MP
Author(s): Hanson MA, Gluckman PD, Ma RCW, Matzen P, Biesma RG
Author(s): Luke A, Cooper RS, Prewitt TE, Adeyemo AA, Forrester TE
Author(s): Centre for Public Health Excellence at NICE, National Collaborating Centre for Primary Care
Author(s): NICE
Author(s): Earland J, Campbell J, Srivastava A
Author(s): International Diabetes Federation (IDF-2011) IDF Diabetes Atlas
Author(s): Esposito K, Maiorino MI, Ciotola M, Di Palo C, Scognamiglio P, et al.
Author(s): Walker KZ, O’Dea K, Gomez M, Girgis S, Colagiuri R
Author(s): Nantel G
Author(s): Wyness L
Author(s): Widanagamage RD, Ekanayake S, Welihinda J
Author(s): Food and Agricultural Organisation/World Health Organisation
Author(s): Burger KNJ
Author(s): Hare-Bruun H, Nielsen BM, Grau K, Oxlund AL, Heitmann BL
Author(s): Aston LM, Gambell JM, Lee DM, Bryant SP, Jebb SA
Author(s): Hassan A, Elobeid T, Kerkadi A, Medhat M, Suheil G
Author(s): Al-Dhaheri AS, Henry CJK, Lightowler HJ, Cheik Ismail LI, Al-Hanourani HM
Author(s): Sharma S, Cruickshank JK
Author(s): Weinrich SP, Priest J, Reynolds W, Godley PA, Tuckson W, et al.
Author(s): Delisle HF, Vioque J, Gil A